ClinicalTrials.gg
CompletedNCT06588088Updated Aug 26, 2025

Cardiorenal and Metabolic Effects of Nighttime Eating

An interventional study of Dietary in Night Eating Syndrome, Metabolic Syndrome and Cardiorenal Syndrome, sponsored by Koc University Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Koc University Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled May 2022, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Metabolic Syndrome with a site in Turkey — 14 open to participants now, 16 under way, none of them phase 3. Metabolic Syndrome · Turkey.

Enrollment
20th of 20
16 · median 76
Started
2022
with 7 others
No phase
16 of 54
1 open now
Registered
30th of 54
by date

Among the 54 studies in Metabolic Syndrome with a site in Turkey, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2022, is one of 16 with no phase, and was the 30th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

14 of the 54 studies in Metabolic Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Metabolic Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

In this study, the investigators are trying to find out of the effect of nighttime eating on metabolism, cardiorenal, hormonal and circadian rhythm, and a study was conducted to examine the effects of diseases that are quite common in internal medicine practice, such as type 2 diabetes mellitus, chronic kidney disease, hypertension, metabolic syndrome and sleep disorders.

Read the detailed description

The Coronavirus Disease (COVID)-19 pandemic, which emerged in recent years, has deeply affected living conditions and has had an impact on societies on eating habits. As shown by some studies, it has been shown that night sleep habits have changed and night nutrition and calorie intake have increased due to reasons related to staying at home, working remotely, and isolation during the pandemic period. However, some recent studies have shown a relationship between nighttime eating and conditions that predispose to metabolic syndrome, such as obesity and hyperglycemia. At the same time, prospective studies on the details of the cardiorenal and metabolic effects of night feeding behavior, which is one of the important predisposing factors for metabolic syndrome, are quite insufficient. Although the importance of nighttime eating habits has begun to be emphasized in recent years with recent randomized cross-controlled studies on this subject, there are not yet enough prospective studies on this subject. In this respect, studies on nighttime eating behavior, which is common in society, are important.In this study, a cross-over design study was conducted on the effectiveness of nighttime eating on metabolism, cardiorenal, hormonal and circadian rhythm, and a study was conducted to examine the effects of diseases that are quite common in internal medicine practice, such as type 2 diabetes mellitus, chronic kidney disease, hypertension, metabolic syndrome and sleep disorders. The investigators aim to create a new and additional perspective on the management, treatment and follow-up of common diseases and to contribute to raising awareness about night nutrition.

03

Conditions studied

  • Night Eating Syndrome
  • Metabolic Syndrome
  • Cardiorenal Syndrome
  • Sleep Disorder

Keywords

  • Night Eating Syndrome
  • Nutrition
  • Metabolic Syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being between the ages of 18-65
  • Being willing to adapt to the desired feeding time and calories
  • (BMI) is between 18-30
  • Not having any systemic disease, not using chronic medication

Exclusion criteria

Exclusion Criteria:

  • -\<18, >65 years old
  • Failure to comply with the regulated nutrition program
  • between \<18 and >30
  • Presence of systemic disease: E.g. Diabetes Mellitus, Chronic Kidney Disease, Coronary Artery Disease, Hypertension etc.
  • Inability to have polygraphy
  • Chronic drug use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Placebo comparator
    Early eaters

    The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week of the study.

    Other: Dietary

  • Active comparator
    Night time Eaters

    The diet of the same healthy volunteers was 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the night time eating syndrome (NES) criteria, after 20.30 in the evening.

    Other: Dietary

Interventions

  • OtherDietary

    The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week, and in the second week, 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the nighttime eating syndrome (NES) criteria, after 20.30 in the evening.

06

What researchers measure

Primary outcomes

  1. Change of the concentration albuminuria in the Nighttime Eating Period

    More than 20% increase during night feeding period

    Time frame: 1 week

  2. Change of the concentration of serum melatonin levels in the Nighttime Eating Period

    More than 50% increase during night feeding period

    Time frame: 1 week

  3. Change of the concentration of serum leptin levels in the Nighttime Eating Period

    More than 50% increase during night feeding period

    Time frame: 1 week

  4. Change of the Concentration of serum ghrelin Levels in the Nighttime Eating Period

    More than 50% increase during night feeding period

    Time frame: 1 week

  5. Change of the concentration of serum total cholesterol, low-density lipoprotein cholesterol, high density lipoprotein cholesterol and triglyceride levels in the Nighttime Eating Period

    More than 20% increase during night feeding period

    Time frame: 1 week

  6. Change of Concentration of serum glucose in the Nighttime Eating Period

    More than 10% increase during night feeding period

    Time frame: 1 week

  7. Change of Concentration of serum insulin in the Nighttime Eating Period

    More than 10% increase during night feeding period

    Time frame: 1 week

  8. Change of concentration of serum Cortisol Level in the Nighttime Eating Period

    More than 50% increase during night feeding period

    Time frame: 1 week

  9. Change of concentration of serum Fibroblast Growth Factor 21 Level in the Nighttime Eating Period

    More than 10% increase during night feeding period

    Time frame: 1 week

  10. Change of the concentration of serum Cytokeratin 18 level in the Nighttime Eating Period

    More than 10% increase during night feeding period

    Time frame: 1 week

  11. Change of value of Apnea Hypopnea Index in the Nighttime Eating Period

    The Apnea-Hypopnea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. Apneas (pauses in breathing) must last for at least 10 seconds and be associated with a decrease in blood oxygenation to be considered. Combining AHI and oxygen desaturation gives an overall sleep apnea severity score that evaluates both the number of sleep breathing disruptions and the degree of oxygen desaturation (low oxygen level in the blood) during said disruptions. The AHI is calculated by dividing the number of apnea events by the number of hours of sleep. The AHI values for adults are categorized as: Normal: AHI\<5 Mild sleep apnea: 5≤AHI\<15 Moderate sleep apnea: 15≤AHI\<30 Severe sleep apnea: AHI≥30More than 10% increase during night feeding period

    Time frame: 1 week

07

Study locations

1 site
  • Koc University Hospital
    Istanbul, 34010, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2023, 19 months.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 19 months is close to that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Sep 19, 2024
StartActual
May 1, 2022
Primary completionActual
Dec 1, 2023
CompletionActual
Dec 1, 2024
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588088
Lead sponsor
Koc University Hospital
Responsible party
Yavuz Erkam Kesgin (Medical Doctor, Resident in Internal Medicine, Koc University Hospital) — Principal investigator
First posted
Sep 19, 2024
Start date
May 1, 2022
Primary completion
Dec 1, 2023
Completion
Dec 1, 2024
Last update
Aug 26, 2025

Study contacts

Mehmet Kanbay, Medical Doctor
study director · Koc University, School Of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion